Caffeine as an Ergogenic Aid: How to Read the ISSN Position Stand

The 2021 International Society of Sports Nutrition (ISSN) position stand places caffeine's most consistent, moderate-to-large benefit in aerobic endurance, at doses of 3 to 6 mg/kg body mass taken roughly 60 minutes before exercise. Effects on muscular strength, sprinting, and team-sport actions are real but smaller and less consistent. And across every modality, the modest average effect sizes hide large differences between individuals, which is the part most summaries skip.

What the position stand actually is

The document, led by Nanci Guest with a large group of co-authors and published in the Journal of the International Society of Sports Nutrition (Guest et al., 2021), is a graded synthesis of existing trials and meta-analyses, not a single experiment. That structure matters for how you read it. A position stand aggregates many studies of varying size and quality, so its headline statements carry different weight depending on how much evidence sits underneath them. The strongest claims rest on dozens of randomized trials pooled into meta-analyses; the weakest rest on a handful of small studies pointing in different directions.

So the useful skill is not memorizing the recommendation. It is learning to see which sentences are load-bearing and which are provisional.

Where the evidence is strongest

Aerobic endurance is the clearest case. The stand describes it as the modality with the most consistent moderate-to-large benefits, and the underlying numbers are worth stating plainly. A meta-analysis of endurance work cited in the document found mean power output improved by roughly 2.9 percent, with an average effect size near 0.22. Time-trial completion improved by around 2.3 percent, effect size near 0.28. Those are small-to-moderate effects in statistical terms, even though 2 to 4 percent can be a meaningful margin in a competitive race.

Two features make the endurance evidence trustworthy. First, it reproduces across cycling, running, swimming, and cross-country skiing, so it is not an artifact of one lab or one sport. Second, the effect survives pooling across many trials, which is a harder test than any single positive study.

The dosing and timing claims are similarly well supported. Benefits appear reliably at 3 to 6 mg/kg, with some signal as low as 2 mg/kg, and the most studied timing is about 60 minutes before exercise, tracking peak plasma concentration. These figures describe what the trials measured across groups rather than what any one reader should expect.

Where the evidence gets thinner

Strength and power tell a messier story. The stand reports small effect sizes, roughly 0.16 to 0.38, for muscular endurance, movement velocity, and strength, with the most meaningful gains in strength-sport athletes. Repeated-sprint performance is explicitly flagged as inconsistent and in need of more work.

Team sports are the most variable of all. The document notes that soccer studies showed gains in distance covered and passing accuracy but not sprint time; basketball improved in some contexts; volleyball benefited on some metrics and not others. When results scatter like that, the honest reading is that any effect is small and easily swamped by everything else that determines a game.

A reader trained to spot load-bearing sentences will notice the language shift. Endurance gets consistent moderate-to-large. Sprinting and team sports get mixed, inconsistent, and requires further investigation. Those hedge words are doing real work.

Why the averages mislead

The single most important caveat in the whole document is that these effect sizes are averages, and the spread around them is wide. A mean improvement of 2.9 percent with a standard deviation of 2.2 percent means some people respond strongly, some barely, and a few may respond negatively.

Genetics is one named source of that spread. More than 95 percent of caffeine is metabolized by the hepatic enzyme CYP1A2, and a common variant (the -163A>C polymorphism) sorts people into faster and slower metabolizers. The stand cites work in which endurance benefits appeared mainly in the AA genotype, while some CC individuals showed performance decrements at higher doses. Evidence for the ADORA2A adenosine-receptor gene is thinner and more preliminary, drawn from small samples, and also bears on caffeine's effects on sleep and anxiety rather than performance alone.

Habituation is genuinely unsettled. The stand summarizes it as equivocal: some studies suggest tolerance builds in low habitual consumers over weeks, others find the ergogenic effect persists regardless of habitual intake. When a synthesis calls its own evidence equivocal, that is the correct place to hold uncertainty rather than pick a side.

This is educational information, not medical advice, and it is a description of what the research population showed rather than guidance for any one person.

Reading the safety language carefully

The stand does not treat more as better. It flags doses around 9 mg/kg as carrying a high incidence of side effects with no added performance value, and notes that the concentration monitored by anti-doping authorities corresponds to intakes several times higher than the amounts shown to help. The performance window and the tolerability window are not the same window, and the document is careful to say so.

How to use a position stand well

Read it as a map of confidence, not a list of instructions. The load-bearing claims here are narrow: aerobic endurance, a defined dose range, a defined timing window, an average effect that is statistically small even when competitively useful. Everything beyond that carries visible hedges, and the between-person variability means a group average is a weak predictor of any single response. Grading evidence this way, by strength of support and size of the caveat, travels well beyond caffeine to almost any performance or health claim you will meet.